← All trials
NCT05324852
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2022
- Primary completion
- Nov 15, 2024
- Completion date
- Jan 15, 2025
- First posted
- Apr 12, 2022
- Last posted
- Oct 18, 2022
- Enrollment
- 830
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
- Hôpital LariboisièreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.